Please wait while the formulary information is being retrieved.
DRUG IMAGES
PENICILLIN VK 250 MG/5 ML SOLN
PENICILLIN VK 500 MG TABLET
PENICILLIN VK 250 MG TABLET
PENICILLIN VK 125 MG/5 ML SOLN
The following indications for PENICILLIN V POTASSIUM (penicillin v potassium) have been approved by the FDA:
Indications:
Acute bacterial otitis media
Erysipelas
Fusospirochetal pharyngitis
Gingivostomatitis
Infection prevention from tooth extraction
Pharyngitis due to Streptococcus pyogenes
Pharyngitis
Pneumococcal acute otitis media
Rheumatic fever prevention
Scarlet fever
Skin and skin structure infection
Staphylococcus aureus skin and skin structure infection
Streptococcus acute otitis media
Tonsillitis due to Streptococcus pyogenes
Upper respiratory pneumococcal infection
Upper respiratory streptococcal infection
Professional Synonyms:
Acute otitis media due to Diplococcus pneumoniae
Acute otitis media due to Fraenkel's Pneumococcus
Acute otitis media due to Pneumococcus
Acute otitis media due to Pneumonococcus
Acute otitis media due to Streptococcus pneumoniae
Acute otitis media due to Streptococcus species
Bacterial otitis media
Epidemic sore throat
Fraenkel-Weichselbaum Pneumococcus acute otitis media
Fusospirochetal infection of the oropharynx
Infection of skin and/or subcutaneous tissue
Infection prophylaxis for tooth extraction
Patch of erysipelas
Pharyngitis due to group A beta-hemolytic streptococci
Pharyngitis due to Streptococcus epidemicus
Pneumococcal upper respiratory tract infection
Rheumatic fever prophylaxis
Rose
Scarlatina
Septic sore throat
Skin and skin soft tissue Staphylococcus aureus infection
Skin and soft tissue skin infection
Streptococcal pharyngitis
Streptococcus pyogenes tonsillitis
Throat inflammation
Upper respiratory Diplococcus pneumoniae infection
Upper respiratory infection due to Streptococcus
Upper respiratory infection from Fraenkel's Pneumococcus
Upper respiratory Streptococcus pneumoniae infection
Upper respiratory tract infection due to Pneumococcus
Upper respiratory tract infection due to S. pneumoniae
URI due to Fraenkel-Weichselbaum Pneumococcus
Vincent's angina
Indications:
Acute bacterial otitis media
Erysipelas
Fusospirochetal pharyngitis
Gingivostomatitis
Infection prevention from tooth extraction
Pharyngitis due to Streptococcus pyogenes
Pharyngitis
Pneumococcal acute otitis media
Rheumatic fever prevention
Scarlet fever
Skin and skin structure infection
Staphylococcus aureus skin and skin structure infection
Streptococcus acute otitis media
Tonsillitis due to Streptococcus pyogenes
Upper respiratory pneumococcal infection
Upper respiratory streptococcal infection
Professional Synonyms:
Acute otitis media due to Diplococcus pneumoniae
Acute otitis media due to Fraenkel's Pneumococcus
Acute otitis media due to Pneumococcus
Acute otitis media due to Pneumonococcus
Acute otitis media due to Streptococcus pneumoniae
Acute otitis media due to Streptococcus species
Bacterial otitis media
Epidemic sore throat
Fraenkel-Weichselbaum Pneumococcus acute otitis media
Fusospirochetal infection of the oropharynx
Infection of skin and/or subcutaneous tissue
Infection prophylaxis for tooth extraction
Patch of erysipelas
Pharyngitis due to group A beta-hemolytic streptococci
Pharyngitis due to Streptococcus epidemicus
Pneumococcal upper respiratory tract infection
Rheumatic fever prophylaxis
Rose
Scarlatina
Septic sore throat
Skin and skin soft tissue Staphylococcus aureus infection
Skin and soft tissue skin infection
Streptococcal pharyngitis
Streptococcus pyogenes tonsillitis
Throat inflammation
Upper respiratory Diplococcus pneumoniae infection
Upper respiratory infection due to Streptococcus
Upper respiratory infection from Fraenkel's Pneumococcus
Upper respiratory Streptococcus pneumoniae infection
Upper respiratory tract infection due to Pneumococcus
Upper respiratory tract infection due to S. pneumoniae
URI due to Fraenkel-Weichselbaum Pneumococcus
Vincent's angina
The following dosing information is available for PENICILLIN V POTASSIUM (penicillin v potassium):
Dosage of penicillin V potassium is expressed in terms of penicillin V. Although dosage of the drug is usually expressed as mg of penicillin V, it may be expressed in terms of penicillin V units.
Potency of penicillin V potassium preparations containing 125, 250, or 500 mg of penicillin V is approximately equivalent to 200,000, 400,000, or 800,000 penicillin V units, respectively.
The American Academy of Pediatrics (AAP) states that the usual dosage of oral penicillin V for the treatment of mild to moderate infections in pediatric patients beyond the neonatal period is 25-75 mg/kg daily given in 3 or 4 divided doses.
Some clinicians recommend that children younger than 5 years of age receive oral penicillin V in a dosage of 125 mg 4 times daily and that those older than 5 years of age receive a dosage of 250-500 mg every 6 hours.
The manufacturers state that pediatric patients 12 years of age or older may receive the usual adult dosage of penicillin V. Some clinicians state that children older than 5 years of age may receive the usual adult dosage of the drug.
Dosage adjustments are not usually necessary in patients with renal impairment. Some clinicians suggest increasing the dosing interval to every 8 hours in patients with creatinine clearance less than 10 mL/minute.
Potency of penicillin V potassium preparations containing 125, 250, or 500 mg of penicillin V is approximately equivalent to 200,000, 400,000, or 800,000 penicillin V units, respectively.
The American Academy of Pediatrics (AAP) states that the usual dosage of oral penicillin V for the treatment of mild to moderate infections in pediatric patients beyond the neonatal period is 25-75 mg/kg daily given in 3 or 4 divided doses.
Some clinicians recommend that children younger than 5 years of age receive oral penicillin V in a dosage of 125 mg 4 times daily and that those older than 5 years of age receive a dosage of 250-500 mg every 6 hours.
The manufacturers state that pediatric patients 12 years of age or older may receive the usual adult dosage of penicillin V. Some clinicians state that children older than 5 years of age may receive the usual adult dosage of the drug.
Dosage adjustments are not usually necessary in patients with renal impairment. Some clinicians suggest increasing the dosing interval to every 8 hours in patients with creatinine clearance less than 10 mL/minute.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| PENICILLIN VK 250 MG TABLET | Maintenance | Adults take 1 tablet (250 mg) by oral route every 6 hours |
| PENICILLIN VK 500 MG TABLET | Maintenance | Adults take 1 tablet (500 mg) by oral route every 8 hours |
| PENICILLIN VK 125 MG/5 ML SOLN | Maintenance | Adults take 10 milliliters (250 mg) by oral route every 8 hours |
| PENICILLIN VK 250 MG/5 ML SOLN | Maintenance | Adults take 5 milliliters (250 mg) by oral route every 8 hours |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| PENICILLIN VK 250 MG TABLET | Maintenance | Adults take 1 tablet (250 mg) by oral route every 6 hours |
| PENICILLIN VK 500 MG TABLET | Maintenance | Adults take 1 tablet (500 mg) by oral route every 8 hours |
| PENICILLIN VK 125 MG/5 ML SOLN | Maintenance | Adults take 10 milliliters (250 mg) by oral route every 8 hours |
| PENICILLIN VK 250 MG/5 ML SOLN | Maintenance | Adults take 5 milliliters (250 mg) by oral route every 8 hours |
The following drug interaction information is available for PENICILLIN V POTASSIUM (penicillin v potassium):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3) |
VIVOTIF |
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Methotrexate/Penicillins SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Penicillins may compete with the renal tubular secretion of methotrexate. CLINICAL EFFECTS: The concurrent use of methotrexate and penicillins may result in elevated levels of methotrexate and methotrexate toxicity, leading to increased risk of severe neurotoxicity, stomatitis, and myelosuppression. PREDISPOSING FACTORS: Risk factors for methotrexate toxicity include: - High-dose oncology regimens - Impaired renal function, ascites, or pleural effusions PATIENT MANAGEMENT: Patients receiving concurrent therapy with methotrexate and penicillins should be monitored closely for elevated methotrexate levels and methotrexate toxicity. The dose and duration of leucovorin rescue therapy may need to be increased. DISCUSSION: Elevated methotrexate levels, signs of methotrexate toxicity, and death have been reported following the concurrent use of methotrexate (both low dose and high dose) and penicillin derivatives. In a patient being treated with high-dose methotrexate (8 G/m2), the concurrent use of amoxicillin resulted in a 56% decrease in the clearance of methotrexate and signs of methotrexate toxicity.(1) There are two cases of methotrexate toxicity following the addition of amoxicillin to low-dose methotrexate therapy (7.5 mg-10 mg weekly) for psoriasis. In another case, a patient was found to have a toxic methotrexate level 12 days after her last dose of weekly methotrexate (7.5 mg). The patient had been treated with amoxicillin followed by flucloxacillin.(2) In a case report, dicloxacillin decreased methotrexate clearance 93%.(4) Flucloxacillin was shown to increase the area-under-curve (AUC) of methotrexate by 7.3% in a study in 10 subjects.(5) In a case report, a patient on low-dose methotrexate (5 mg) developed methotrexate pneumonia following the addition of flucloxacillin to his regimen.(5) In a patient being treated with high-dose methotrexate (12 G/m2), the concurrent use of mezlocillin increased the half-life of methotrexate from 10.1 to 27.2 hours.(6) In a case report, a patient developed methotrexate toxicity following the addition of penicillin V potassium to his methotrexate (50 mg weekly).(7) In a case report, penicillin decreased methotrexate clearance 36%.(4) In one report, leucovorin rescue therapy had to be continued for 192 hours following the concurrent use of methotrexate (3 G/m2) and piperacillin. During cycles without concurrent piperacillin, leucovorin rescue therapy was only required for 72 hours.(8) There are two reports of neutropenia and death following the concurrent use of piperacillin and low-dose methotrexate (2.5 mg three times weekly in one patient, 5 mg weekly in another) for psoriasis. One of these patients also received flucloxacillin. (3) In another case report, the concurrent use of piperacillin decreased methotrexate clearance by 67%.(4) In a case report, ticarcillin decreased methotrexate clearance by 60%.(4) |
JYLAMVO, METHOTREXATE, METHOTREXATE SODIUM, OTREXUP, RASUVO, TREXALL, XATMEP |
| Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores. |
VOWST |
There are 2 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Oral Contraceptives/Penicillins SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Estrogens and progesterones are extensively excreted in bile, principally as glycuronide conjugates. Subsequently, they undergo enterohepatic circulation where bacterial hydrolysis occurs, allowing for reabsorption of the oral contraceptives through the bowel wall and eventual urinary excretion. Treatment with antibiotics destroys the gut flora and prevents steroid reabsorption, resulting in lower than normal concentrations of the contraceptive and excretion via the feces rather than the urine. CLINICAL EFFECTS: May observe reduced pharmacologic effects of oral contraceptives with resultant breakthrough bleeding and pregnancy. Reduced effects may be seen for several days after discontinuation of antibiotic therapy. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Current guidelines suggest that additional precautions are not necessary when non-enzyme inducing antibiotics are used concurrently with hormonal contraceptives; however, some patients may still prefer to use an additional method of contraception. DISCUSSION: Evidence for this interaction is limited and conflicting; however, the CDC and the Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit no longer recommend use of a backup contraceptive method during use of a non-enzyme inducing antibiotic. Reports of breakthrough bleeding and loss of contraceptive protection leading to unwanted pregnancies have occurred in women taking oral contraceptive agents who received concurrent ampicillin, amoxicillin, penicillin G, or oxacillin. Several studies have shown that the administration of ampicillin or penicillin to pregnant and nonpregnant women resulted in lowered urinary estrogen excretion, in some women as soon as three days after ampicillin therapy began. However in one small prospective study, plasma ethinyl estradiol concentrations showed a tendency to decrease during ampicillin administration on the third, fourth, and fifth morning of ampicillin administration, but were never lower than pretreatment values. In another small prospective study of women taking low dose combination contraceptives, concurrent ampicillin therapy neither altered the plasma levels nor the AUC of norethisterone and ethinyl estradiol. In addition, progesterone levels were in an anovulatory range. In another prospective study of 13 women taking long term oral contraceptive steroids, concurrent ampicillin was not associated with any significant changes in plasma concentrations of ethinyl estradiol, levonorgestrel, follicle stimulating hormone or progesterone, although lower concentrations of ethinyl estradiol were noted in two women. |
2-METHOXYESTRADIOL, AFIRMELLE, ALTAVERA, ALYACEN, AMETHIA, AMETHYST, APRI, ARANELLE, ASHLYNA, AUBRA, AUBRA EQ, AUROVELA, AUROVELA 24 FE, AUROVELA FE, AVIANE, AYUNA, AZURETTE, BALCOLTRA, BALZIVA, BEYAZ, BLISOVI 24 FE, BLISOVI FE, BRIELLYN, CAMILA, CAMRESE, CAMRESE LO, CAZIANT, CHARLOTTE 24 FE, CHATEAL EQ, CRYSELLE, CYRED, CYRED EQ, DASETTA, DAYSEE, DEBLITANE, DESOGESTR-ETH ESTRAD ETH ESTRA, DIETHYLSTILBESTROL, DOLISHALE, DROSPIRENONE-ETH ESTRA-LEVOMEF, DROSPIRENONE-ETHINYL ESTRADIOL, ELINEST, ELLA, EMZAHH, ENPRESSE, ENSKYCE, ERRIN, ESTARYLLA, ESTRADIOL, ESTRADIOL BENZOATE, ESTRADIOL CYPIONATE, ESTRADIOL HEMIHYDRATE, ESTRADIOL HEMIHYDRATE MICRO, ESTRADIOL MICRONIZED, ESTRADIOL VALERATE, ESTRIOL, ESTRIOL MICRONIZED, ESTRONE, ETHINYL ESTRADIOL, ETHYNODIOL-ETHINYL ESTRADIOL, FALMINA, FEIRZA, FEMLYV, FINZALA, GEMMILY, HAILEY, HAILEY 24 FE, HAILEY FE, HEATHER, ICLEVIA, INCASSIA, ISIBLOOM, JAIMIESS, JASMIEL, JENCYCLA, JOLESSA, JOYEAUX, JULEBER, JUNEL, JUNEL FE, JUNEL FE 24, KAITLIB FE, KALLIGA, KARIVA, KELNOR 1-35, KELNOR 1-50, KURVELO, LARIN, LARIN 24 FE, LARIN FE, LAYOLIS FE, LEENA, LESSINA, LEVONEST, LEVONORG-ETH ESTRAD ETH ESTRAD, LEVONORG-ETH ESTRAD-FE BISGLYC, LEVONORGESTREL-ETH ESTRADIOL, LEVORA-28, LO LOESTRIN FE, LO-ZUMANDIMINE, LOESTRIN, LOESTRIN FE, LOJAIMIESS, LORYNA, LOW-OGESTREL, LUTERA, LYLEQ, LYZA, MARLISSA, MERZEE, MIBELAS 24 FE, MICROGESTIN, MICROGESTIN FE, MILI, MINZOYA, MONO-LINYAH, NATAZIA, NECON, NEXTSTELLIS, NIKKI, NORA-BE, NORETHIN-ETH ESTRA-FERROUS FUM, NORETHINDRON-ETHINYL ESTRADIOL, NORETHINDRONE, NORETHINDRONE-E.ESTRADIOL-IRON, NORGESTIMATE-ETHINYL ESTRADIOL, NORTREL, NYLIA, OCELLA, ORTHO TRI-CYCLEN, ORTHO-NOVUM, PHILITH, PIMTREA, PORTIA, RECLIPSEN, RIVELSA, SAFYRAL, SETLAKIN, SHAROBEL, SIMLIYA, SIMPESSE, SLYND, SPRINTEC, SRONYX, SYEDA, TARINA 24 FE, TARINA FE, TARINA FE 1-20 EQ, TAYTULLA, TILIA FE, TRI-ESTARYLLA, TRI-LEGEST FE, TRI-LINYAH, TRI-LO-ESTARYLLA, TRI-LO-MARZIA, TRI-LO-MILI, TRI-LO-SPRINTEC, TRI-MILI, TRI-SPRINTEC, TRI-VYLIBRA, TRI-VYLIBRA LO, TRIVORA-28, TULANA, TURQOZ, TYBLUME, VALTYA, VELIVET, VESTURA, VIENVA, VIORELE, VOLNEA, VYFEMLA, VYLIBRA, WERA, WYMZYA FE, XARAH FE, XELRIA FE, YASMIN 28, YAZ, ZARAH, ZOVIA 1-35, ZUMANDIMINE |
| Selected Anticoagulants (Vit K antag)/Selected Penicillins SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Unknown. CLINICAL EFFECTS: Large doses of parenterally administered penicillins and oral amoxicillin appear to increase the risk of bleeding during concurrent administration of anticoagulants. PREDISPOSING FACTORS: Renal failure may predispose patients to penicillin-induced coagulation abnormalities. A study suggests that various inflammatory syndromes or the nature of the infection can affect INR levels. The risk for bleeding episodes may be greater in patients with additional disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs). PATIENT MANAGEMENT: Monitor patient INR for an increase in the hypoprothrombinemic response to anticoagulants during concomitant administration of penicillins. Adjust the dose of warfarin accordingly. When concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin and/or hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug. DISCUSSION: High dose parenteral administration of penicillins and oral amoxicillin have been reported to cause an increase in the hypoprothrombinemic effects of warfarin producing bleeding. Significant clinical effects have been reported with combined administration of warfarin and either carbenicillin or penicillin G. There have been several case reports and retrospective reviews documenting increased acenocoumarol and warfarin effects, including bleeding, following the addition of amoxicillin, with and without clavulanic acid, to therapy. In a randomized controlled trial, adult ambulatory patients that had no recent and ongoing infectious or inflammatory conditions received warfarin to a target INR between 2 and 3 with amoxicillin-clavulanic acid (1 gram twice daily for seven days) or placebo. The results showed the mean maximum INR increase from baseline to day 10 did not differ between amoxicillin/clavulanic acid (0.22 +/- 0.3) and the placebo period (0.24 +/- 0.6, p = 0.94). No patient experienced an INR of greater than 3.5. No bleeding events were reported during the entire study. A prospective cross-sectional observational study in 120 patients evaluated warfarin drug interactions, particularly with high-dose amoxicillin/clavulanate. The study found that patients on amoxicillin/clavulanate had a relative risk of having an INR >=4 of 4.8 compared to patients not on amoxicillin/clavulanate (95% CI 2.1-11.3, p < 0.001). This risk was primarily driven by patients on high-dose amoxicillin/clavulanate, who were 5.8 times more likely to have INR >=4 (95% CI 3.5-9.6, p<0.001). Significantly more patients on high-dose than normal dose amoxicillin/clavulanate had an INR value >= 4 (87.5% v. 28.9%, respectively). Nine out of ten patients who experienced bleeding during hospitalization were prescribed amoxicillin/clavulanate. A large systematic review was performed on 72 warfarin drug-drug interactions studies that reported on bleeding, thromboembolic events, or death. Most studies were retrospective cohorts. A meta-analysis of 11 of those studies found a higher rate of clinically significant bleeding in patients on warfarin and antimicrobials (OR=1.63; 95% CI 1.45-1.83). Increased bleeding risk was also seen in subgroup analyses with penicillins (OR=1.59; 95% CI 1.14-2.20) and amoxicillin (OR=1.78; 95% CI 1.14-2.79). A case-control nested cohort study of Medicare beneficiaries with warfarin prescriptions was evaluated for antibiotic use and warfarin toxicity in older adults. An increased risk of bleeding was associated with penicillins with an adjusted odds ratio of 1.92. Parenteral penicillins linked to this monograph include: almecillin, amdinocillin, amoxicillin, ampicillin, azlocillin, bacampicillin, carbenicillin, cyclacillin, hetacillin, mezlocillin, penicillin, penicillin G, penicillin V, phenethicillin, piperacillin, and ticarcillin. Oral penicillins linked to this monograph include: amoxicillin and penicillin. |
ANISINDIONE, DICUMAROL, JANTOVEN, WARFARIN SODIUM |
The following contraindication information is available for PENICILLIN V POTASSIUM (penicillin v potassium):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Clostridioides difficile infection |
There are 0 moderate contraindications.
The following adverse reaction information is available for PENICILLIN V POTASSIUM (penicillin v potassium):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 27 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Anaphylaxis Exfoliative dermatitis Urticaria |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests Acute generalized exanthematous pustulosis Agranulocytosis Autoimmune hemolytic anemia Clostridioides difficile infection Crystalluria DRESS syndrome Drug-induced hepatitis Enterocolitis Eosinophilia Erythema multiforme Furred tongue Hypersensitivity angiitis Idiopathic thrombocytopenic purpura Interstitial nephritis Laryngeal edema Leukopenia Maculopapular rash Obstructive hyperbilirubinemia Seizure disorder Serum sickness Stevens-johnson syndrome Thrombocytopenic disorder Toxic epidermal necrolysis |
There are 16 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Diarrhea Nausea Skin rash Vomiting Vulvovaginal candidiasis |
Abdominal pain with cramps Pruritus of skin |
| Rare/Very Rare |
|---|
|
Acute cognitive impairment Agitation Anemia Behavioral disorders Dental discoloration Dizziness Insomnia Mucocutaneous candidiasis Symptoms of anxiety |
The following precautions are available for PENICILLIN V POTASSIUM (penicillin v potassium):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Available data regarding use of penicillin V in pregnant women, including first-trimester exposures, have not revealed evidence of an association between the drug and congenital defects. Some clinicians state that penicillin V is considered low risk and safe for use during pregnancy.
Penicillin V is distributed into milk. Some clinicians state that oral penicillin V usually is considered compatible with breast-feeding; others state that the drug should be used with caution in nursing women.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for PENICILLIN V POTASSIUM (penicillin v potassium):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for PENICILLIN V POTASSIUM (penicillin v potassium)'s list of indications:
| Acute bacterial otitis media | |
| H66 | Suppurative and unspecified otitis media |
| H66.0 | Acute suppurative otitis media |
| H66.00 | Acute suppurative otitis media without spontaneous rupture of ear drum |
| H66.001 | Acute suppurative otitis media without spontaneous rupture of ear drum, right ear |
| H66.002 | Acute suppurative otitis media without spontaneous rupture of ear drum, left ear |
| H66.003 | Acute suppurative otitis media without spontaneous rupture of ear drum, bilateral |
| H66.004 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, right ear |
| H66.005 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, left ear |
| H66.006 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, bilateral |
| H66.007 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.009 | Acute suppurative otitis media without spontaneous rupture of ear drum, unspecified ear |
| H66.01 | Acute suppurative otitis media with spontaneous rupture of ear drum |
| H66.011 | Acute suppurative otitis media with spontaneous rupture of ear drum, right ear |
| H66.012 | Acute suppurative otitis media with spontaneous rupture of ear drum, left ear |
| H66.013 | Acute suppurative otitis media with spontaneous rupture of ear drum, bilateral |
| H66.014 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, right ear |
| H66.015 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, left ear |
| H66.016 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, bilateral |
| H66.017 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.019 | Acute suppurative otitis media with spontaneous rupture of ear drum, unspecified ear |
| H66.4 | Suppurative otitis media, unspecified |
| H66.40 | Suppurative otitis media, unspecified, unspecified ear |
| H66.41 | Suppurative otitis media, unspecified, right ear |
| H66.42 | Suppurative otitis media, unspecified, left ear |
| H66.43 | Suppurative otitis media, unspecified, bilateral |
| H66.9 | Otitis media, unspecified |
| H66.90 | Otitis media, unspecified, unspecified ear |
| H66.91 | Otitis media, unspecified, right ear |
| H66.92 | Otitis media, unspecified, left ear |
| H66.93 | Otitis media, unspecified, bilateral |
| Erysipelas | |
| A46 | Erysipelas |
| Fusospirochetal pharyngitis | |
| A69.1 | Other vincent's infections |
| Gingivostomatitis | |
| K05.10 | Chronic gingivitis, plaque induced |
| Pharyngitis | |
| J02 | Acute pharyngitis |
| J02.0 | Streptococcal pharyngitis |
| J02.8 | Acute pharyngitis due to other specified organisms |
| J02.9 | Acute pharyngitis, unspecified |
| Pharyngitis due to streptococcus pyogenes | |
| J02.0 | Streptococcal pharyngitis |
| Pneumococcal acute otitis media | |
| B95.3 | Streptococcus pneumoniae as the cause of diseases classified elsewhere |
| H66.0 | Acute suppurative otitis media |
| H66.00 | Acute suppurative otitis media without spontaneous rupture of ear drum |
| H66.001 | Acute suppurative otitis media without spontaneous rupture of ear drum, right ear |
| H66.002 | Acute suppurative otitis media without spontaneous rupture of ear drum, left ear |
| H66.003 | Acute suppurative otitis media without spontaneous rupture of ear drum, bilateral |
| H66.004 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, right ear |
| H66.005 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, left ear |
| H66.006 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, bilateral |
| H66.007 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.009 | Acute suppurative otitis media without spontaneous rupture of ear drum, unspecified ear |
| H66.01 | Acute suppurative otitis media with spontaneous rupture of ear drum |
| H66.011 | Acute suppurative otitis media with spontaneous rupture of ear drum, right ear |
| H66.012 | Acute suppurative otitis media with spontaneous rupture of ear drum, left ear |
| H66.013 | Acute suppurative otitis media with spontaneous rupture of ear drum, bilateral |
| H66.014 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, right ear |
| H66.015 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, left ear |
| H66.016 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, bilateral |
| H66.017 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.019 | Acute suppurative otitis media with spontaneous rupture of ear drum, unspecified ear |
| H66.4 | Suppurative otitis media, unspecified |
| H66.40 | Suppurative otitis media, unspecified, unspecified ear |
| H66.41 | Suppurative otitis media, unspecified, right ear |
| H66.42 | Suppurative otitis media, unspecified, left ear |
| H66.43 | Suppurative otitis media, unspecified, bilateral |
| H66.9 | Otitis media, unspecified |
| H66.91 | Otitis media, unspecified, right ear |
| H66.92 | Otitis media, unspecified, left ear |
| H66.93 | Otitis media, unspecified, bilateral |
| Rheumatic fever prevention | |
| B95.0 | Streptococcus, group a, as the cause of diseases classified elsewhere |
| J02.0 | Streptococcal pharyngitis |
| J03.00 | Acute streptococcal tonsillitis, unspecified |
| Scarlet fever | |
| A38 | Scarlet fever |
| A38.0 | Scarlet fever with otitis media |
| A38.1 | Scarlet fever with myocarditis |
| A38.8 | Scarlet fever with other complications |
| A38.9 | Scarlet fever, uncomplicated |
| Skin and skin structure infection | |
| H05.01 | Cellulitis of orbit |
| H05.011 | Cellulitis of right orbit |
| H05.012 | Cellulitis of left orbit |
| H05.013 | Cellulitis of bilateral orbits |
| H05.019 | Cellulitis of unspecified orbit |
| H60.1 | Cellulitis of external ear |
| H60.10 | Cellulitis of external ear, unspecified ear |
| H60.11 | Cellulitis of right external ear |
| H60.12 | Cellulitis of left external ear |
| H60.13 | Cellulitis of external ear, bilateral |
| K12.2 | Cellulitis and abscess of mouth |
| L03 | Cellulitis and acute lymphangitis |
| L03.0 | Cellulitis and acute lymphangitis of finger and toe |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| N48.22 | Cellulitis of corpus cavernosum and penis |
| Staphylococcus aureus skin and skin structure infection | |
| B95.6 | Staphylococcus aureus as the cause of diseases classified elsewhere |
| H60.1 | Cellulitis of external ear |
| H60.10 | Cellulitis of external ear, unspecified ear |
| H60.11 | Cellulitis of right external ear |
| H60.12 | Cellulitis of left external ear |
| H60.13 | Cellulitis of external ear, bilateral |
| J34.0 | Abscess, furuncle and carbuncle of nose |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L02.0 | Cutaneous abscess, furuncle and carbuncle of face |
| L02.02 | Furuncle of face |
| L02.03 | Carbuncle of face |
| L02.1 | Cutaneous abscess, furuncle and carbuncle of neck |
| L02.12 | Furuncle of neck |
| L02.13 | Carbuncle of neck |
| L02.2 | Cutaneous abscess, furuncle and carbuncle of trunk |
| L02.22 | Furuncle of trunk |
| L02.221 | Furuncle of abdominal wall |
| L02.222 | Furuncle of back [any part, except buttock] |
| L02.223 | Furuncle of chest wall |
| L02.224 | Furuncle of groin |
| L02.225 | Furuncle of perineum |
| L02.226 | Furuncle of umbilicus |
| L02.229 | Furuncle of trunk, unspecified |
| L02.23 | Carbuncle of trunk |
| L02.231 | Carbuncle of abdominal wall |
| L02.232 | Carbuncle of back [any part, except buttock] |
| L02.233 | Carbuncle of chest wall |
| L02.234 | Carbuncle of groin |
| L02.235 | Carbuncle of perineum |
| L02.236 | Carbuncle of umbilicus |
| L02.239 | Carbuncle of trunk, unspecified |
| L02.3 | Cutaneous abscess, furuncle and carbuncle of buttock |
| L02.32 | Furuncle of buttock |
| L02.33 | Carbuncle of buttock |
| L02.4 | Cutaneous abscess, furuncle and carbuncle of limb |
| L02.42 | Furuncle of limb |
| L02.421 | Furuncle of right axilla |
| L02.422 | Furuncle of left axilla |
| L02.423 | Furuncle of right upper limb |
| L02.424 | Furuncle of left upper limb |
| L02.425 | Furuncle of right lower limb |
| L02.426 | Furuncle of left lower limb |
| L02.429 | Furuncle of limb, unspecified |
| L02.43 | Carbuncle of limb |
| L02.431 | Carbuncle of right axilla |
| L02.432 | Carbuncle of left axilla |
| L02.433 | Carbuncle of right upper limb |
| L02.434 | Carbuncle of left upper limb |
| L02.435 | Carbuncle of right lower limb |
| L02.436 | Carbuncle of left lower limb |
| L02.439 | Carbuncle of limb, unspecified |
| L02.5 | Cutaneous abscess, furuncle and carbuncle of hand |
| L02.52 | Furuncle hand |
| L02.521 | Furuncle right hand |
| L02.522 | Furuncle left hand |
| L02.529 | Furuncle unspecified hand |
| L02.53 | Carbuncle of hand |
| L02.531 | Carbuncle of right hand |
| L02.532 | Carbuncle of left hand |
| L02.539 | Carbuncle of unspecified hand |
| L02.6 | Cutaneous abscess, furuncle and carbuncle of foot |
| L02.62 | Furuncle of foot |
| L02.621 | Furuncle of right foot |
| L02.622 | Furuncle of left foot |
| L02.629 | Furuncle of unspecified foot |
| L02.63 | Carbuncle of foot |
| L02.631 | Carbuncle of right foot |
| L02.632 | Carbuncle of left foot |
| L02.639 | Carbuncle of unspecified foot |
| L02.8 | Cutaneous abscess, furuncle and carbuncle of other sites |
| L02.82 | Furuncle of other sites |
| L02.821 | Furuncle of head [any part, except face] |
| L02.828 | Furuncle of other sites |
| L02.83 | Carbuncle of other sites |
| L02.831 | Carbuncle of head [any part, except face] |
| L02.838 | Carbuncle of other sites |
| L02.9 | Cutaneous abscess, furuncle and carbuncle, unspecified |
| L02.92 | Furuncle, unspecified |
| L02.93 | Carbuncle, unspecified |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| N48.22 | Cellulitis of corpus cavernosum and penis |
| Streptococcus acute otitis media | |
| B95.0 | Streptococcus, group a, as the cause of diseases classified elsewhere |
| B95.4 | Other streptococcus as the cause of diseases classified elsewhere |
| B95.5 | Unspecified streptococcus as the cause of diseases classified elsewhere |
| H66.0 | Acute suppurative otitis media |
| H66.00 | Acute suppurative otitis media without spontaneous rupture of ear drum |
| H66.001 | Acute suppurative otitis media without spontaneous rupture of ear drum, right ear |
| H66.002 | Acute suppurative otitis media without spontaneous rupture of ear drum, left ear |
| H66.003 | Acute suppurative otitis media without spontaneous rupture of ear drum, bilateral |
| H66.004 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, right ear |
| H66.005 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, left ear |
| H66.006 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, bilateral |
| H66.007 | Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.009 | Acute suppurative otitis media without spontaneous rupture of ear drum, unspecified ear |
| H66.01 | Acute suppurative otitis media with spontaneous rupture of ear drum |
| H66.011 | Acute suppurative otitis media with spontaneous rupture of ear drum, right ear |
| H66.012 | Acute suppurative otitis media with spontaneous rupture of ear drum, left ear |
| H66.013 | Acute suppurative otitis media with spontaneous rupture of ear drum, bilateral |
| H66.014 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, right ear |
| H66.015 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, left ear |
| H66.016 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, bilateral |
| H66.017 | Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, unspecified ear |
| H66.019 | Acute suppurative otitis media with spontaneous rupture of ear drum, unspecified ear |
| H66.4 | Suppurative otitis media, unspecified |
| H66.40 | Suppurative otitis media, unspecified, unspecified ear |
| H66.41 | Suppurative otitis media, unspecified, right ear |
| H66.42 | Suppurative otitis media, unspecified, left ear |
| H66.43 | Suppurative otitis media, unspecified, bilateral |
| H66.9 | Otitis media, unspecified |
| H66.90 | Otitis media, unspecified, unspecified ear |
| H66.91 | Otitis media, unspecified, right ear |
| H66.92 | Otitis media, unspecified, left ear |
| H66.93 | Otitis media, unspecified, bilateral |
| Tonsillitis due to streptococcus pyogenes | |
| J03.0 | Streptococcal tonsillitis |
| J03.00 | Acute streptococcal tonsillitis, unspecified |
| J03.01 | Acute recurrent streptococcal tonsillitis |
| Upper respiratory pneumococcal infection | |
| B95.3 | Streptococcus pneumoniae as the cause of diseases classified elsewhere |
| J00 | Acute nasopharyngitis [common cold] |
| J01 | Acute sinusitis |
| J01.0 | Acute maxillary sinusitis |
| J01.00 | Acute maxillary sinusitis, unspecified |
| J01.01 | Acute recurrent maxillary sinusitis |
| J01.1 | Acute frontal sinusitis |
| J01.10 | Acute frontal sinusitis, unspecified |
| J01.11 | Acute recurrent frontal sinusitis |
| J01.2 | Acute ethmoidal sinusitis |
| J01.20 | Acute ethmoidal sinusitis, unspecified |
| J01.21 | Acute recurrent ethmoidal sinusitis |
| J01.3 | Acute sphenoidal sinusitis |
| J01.30 | Acute sphenoidal sinusitis, unspecified |
| J01.31 | Acute recurrent sphenoidal sinusitis |
| J01.4 | Acute pansinusitis |
| J01.40 | Acute pansinusitis, unspecified |
| J01.41 | Acute recurrent pansinusitis |
| J01.8 | Other acute sinusitis |
| J01.80 | Other acute sinusitis |
| J01.81 | Other acute recurrent sinusitis |
| J01.9 | Acute sinusitis, unspecified |
| J01.90 | Acute sinusitis, unspecified |
| J01.91 | Acute recurrent sinusitis, unspecified |
| J02 | Acute pharyngitis |
| J02.0 | Streptococcal pharyngitis |
| J02.9 | Acute pharyngitis, unspecified |
| J03 | Acute tonsillitis |
| J03.0 | Streptococcal tonsillitis |
| J03.00 | Acute streptococcal tonsillitis, unspecified |
| J03.01 | Acute recurrent streptococcal tonsillitis |
| J03.9 | Acute tonsillitis, unspecified |
| J03.90 | Acute tonsillitis, unspecified |
| J03.91 | Acute recurrent tonsillitis, unspecified |
| J04 | Acute laryngitis and tracheitis |
| J04.0 | Acute laryngitis |
| J04.1 | Acute tracheitis |
| J04.10 | Acute tracheitis without obstruction |
| J04.11 | Acute tracheitis with obstruction |
| J04.2 | Acute laryngotracheitis |
| J04.3 | Supraglottitis, unspecified |
| J04.30 | Supraglottitis, unspecified, without obstruction |
| J04.31 | Supraglottitis, unspecified, with obstruction |
| J05 | Acute obstructive laryngitis [croup] and epiglottitis |
| J05.0 | Acute obstructive laryngitis [croup] |
| J05.1 | Acute epiglottitis |
| J05.10 | Acute epiglottitis without obstruction |
| J05.11 | Acute epiglottitis with obstruction |
| J06 | Acute upper respiratory infections of multiple and unspecified sites |
| J06.0 | Acute laryngopharyngitis |
| J06.9 | Acute upper respiratory infection, unspecified |
| Upper respiratory streptococcal infection | |
| B95.0 | Streptococcus, group a, as the cause of diseases classified elsewhere |
| B95.3 | Streptococcus pneumoniae as the cause of diseases classified elsewhere |
| B95.4 | Other streptococcus as the cause of diseases classified elsewhere |
| B95.5 | Unspecified streptococcus as the cause of diseases classified elsewhere |
| J00 | Acute nasopharyngitis [common cold] |
| J01 | Acute sinusitis |
| J01.0 | Acute maxillary sinusitis |
| J01.00 | Acute maxillary sinusitis, unspecified |
| J01.01 | Acute recurrent maxillary sinusitis |
| J01.1 | Acute frontal sinusitis |
| J01.10 | Acute frontal sinusitis, unspecified |
| J01.11 | Acute recurrent frontal sinusitis |
| J01.2 | Acute ethmoidal sinusitis |
| J01.20 | Acute ethmoidal sinusitis, unspecified |
| J01.21 | Acute recurrent ethmoidal sinusitis |
| J01.3 | Acute sphenoidal sinusitis |
| J01.30 | Acute sphenoidal sinusitis, unspecified |
| J01.31 | Acute recurrent sphenoidal sinusitis |
| J01.4 | Acute pansinusitis |
| J01.40 | Acute pansinusitis, unspecified |
| J01.41 | Acute recurrent pansinusitis |
| J01.8 | Other acute sinusitis |
| J01.80 | Other acute sinusitis |
| J01.81 | Other acute recurrent sinusitis |
| J01.9 | Acute sinusitis, unspecified |
| J01.90 | Acute sinusitis, unspecified |
| J01.91 | Acute recurrent sinusitis, unspecified |
| J02 | Acute pharyngitis |
| J02.0 | Streptococcal pharyngitis |
| J02.9 | Acute pharyngitis, unspecified |
| J03 | Acute tonsillitis |
| J03.0 | Streptococcal tonsillitis |
| J03.00 | Acute streptococcal tonsillitis, unspecified |
| J03.01 | Acute recurrent streptococcal tonsillitis |
| J03.9 | Acute tonsillitis, unspecified |
| J03.90 | Acute tonsillitis, unspecified |
| J03.91 | Acute recurrent tonsillitis, unspecified |
| J04 | Acute laryngitis and tracheitis |
| J04.0 | Acute laryngitis |
| J04.1 | Acute tracheitis |
| J04.10 | Acute tracheitis without obstruction |
| J04.11 | Acute tracheitis with obstruction |
| J04.2 | Acute laryngotracheitis |
| J04.3 | Supraglottitis, unspecified |
| J04.30 | Supraglottitis, unspecified, without obstruction |
| J04.31 | Supraglottitis, unspecified, with obstruction |
| J05 | Acute obstructive laryngitis [croup] and epiglottitis |
| J05.0 | Acute obstructive laryngitis [croup] |
| J05.1 | Acute epiglottitis |
| J05.10 | Acute epiglottitis without obstruction |
| J05.11 | Acute epiglottitis with obstruction |
| J06 | Acute upper respiratory infections of multiple and unspecified sites |
| J06.0 | Acute laryngopharyngitis |
| J06.9 | Acute upper respiratory infection, unspecified |
Formulary Reference Tool